Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction
Status:
Recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-861
administered once daily for 12 weeks in subjects with heart failure with reduced ejection
fraction (HFrEF) who are on a stable, guideline-directed medical therapy for heart failure.